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Abstract
Background: Simultaneous consideration of two neuropathological traits related to Alzheimer’s disease (AD) has not
been attempted in a genome-wide association study.
Methods: We conducted genome-wide pleiotropy analyses using association summary statistics from the Beecham et
al. study (PLoS Genet 10:e1004606, 2014) for AD-related neuropathological traits, including neuritic plaque (NP),
neurofibrillary tangle (NFT), and cerebral amyloid angiopathy (CAA). Significant findings were further examined
by expression quantitative trait locus and differentially expressed gene analyses in AD vs. control brains using
gene expression data.
Results: Genome-wide significant pleiotropic associations were observed for the joint model of NP and NFT (NP + NFT)
with the single-nucleotide polymorphism (SNP) rs34487851 upstream of C2orf40 (alias ECRG4, P = 2.4 × 10−8) and for the
joint model of NFT and CAA (NFT + CAA) with the HDAC9 SNP rs79524815 (P = 1.1 × 10−8). Gene-based testing revealed
study-wide significant associations (P ≤ 2.0 × 10−6) for the NFT + CAA outcome with adjacent genes TRAPPC12, TRAPPC12-
AS1, and ADI1. Risk alleles of proxy SNPs for rs79524815 were associated with significantly lower expression of HDAC9 in
the brain (P = 3.0 × 10−3), and HDAC9 was significantly downregulated in subjects with AD compared with
control subjects in the prefrontal (P = 7.9 × 10−3) and visual (P = 5.6 × 10−4) cortices.
Conclusions: Our findings suggest that pleiotropy analysis is a useful approach to identifying novel genetic
associations with complex diseases and their endophenotypes. Functional studies are needed to determine
whether ECRG4 or HDAC9 is plausible as a therapeutic target.
Keywords: Alzheimer’s disease, Neuropathological traits, Genome-wide association study, Pleiotropy analysis,
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Background
Alzheimer’s disease (AD) is the most common type of
dementia in persons aged 65 years and older [1, 2]. Patho-
logically, it is characterized primarily by the appearance of
both neuritic plaques (NPs) containing oligomers of β-
amyloid and neurofibrillary tangles (NFTs), accompanied
by a progressive loss of neurons in the brain [3, 4]. Also,
cerebral amyloid angiopathy (CAA), which is caused by
aggregates of β-amyloid in walls of blood vessels in the
brain, is found in as many as 90% of autopsy-confirmed
AD cases [5]. Previously, Beecham et al. identified
multiple significant gene associations in a genome-wide
association study (GWAS) for several AD-related neuro-
pathological traits, including NP, NFT, and CAA mea-
sured in brains from subjects with pathologically
confirmed AD cases and from control subjects with no
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evidence of neurological disease [6]. We hypothesized that
additional novel associations could be identified in models
allowing a genetic variant to influence more than one trait
(i.e., pleiotropy). In this study, we performed genome-wide
pleiotropy analyses of joint models of NP, NFT, and CAA
using summary data from the previous study [6].
Methods
Study population, neuropathological trait selection, and
data processing
We obtained summary statistics from univariate GWAS
of NP, NFT, and CAA [6]. These results were derived
from meta-analyses of 12 studies including 3598 subjects
(3135 AD cases, 463 controls) of European ancestry.
Neuropathological data for the entire sample were
reviewed and harmonized by one neuropathologist for
consistency across studies [6]. Although Beecham et al.
[6] also evaluated Lewy body disease, hippocampal scler-
osis, and vascular brain disease, we limited our present
analyses to neuropathological outcomes most directly
linked to AD and moderately correlated with each other
(i.e., NP, NFT, and CAA). Uncorrelated traits are un-
likely to show significant pleiotropic associations, and
results from pleiotropy analysis will be similar to those
from univariate models (i.e., single phenotype) if the
traits are highly correlated. Details of subject re-
cruitment, genotyping, genotype imputation, quality
control procedures, population substructure analysis,
and statistical methods for association analyses of
individual traits were reported previously [6, 7]. Sam-
ple demography of the 3598 subjects with autopsied
brains and genotypes (3135 cases and 463 controls) is
described in Additional file 1: Table S1.
Univariate genome-wide association analyses
Results from the association tests by Beecham et al. [6]
in each dataset for each neuropathologic trait with geno-
types imputed using the 1000 Genomes Project refer-
ence panel (GRCh37 at December 2010) for a genome-
wide set of single-nucleotide polymorphisms (SNPs)
were obtained using ordinal logistic regression models
including the first three principal components of ances-
try as covariates to account for population substructure
[6]. NP and NFT measures were analyzed in well-
established ordinal rankings (NPs: none, sparse, moder-
ate, and frequent by Consortium to Establish a Registry
for Alzheimer’s Disease [“CERAD”] scoring [8]; NFT:
none, transentorhinal, limbic, and isocortical by Braak
and Braak staging [9]), and CAA was analyzed as a bin-
ary trait (present or absent). Full details of these analyses
are reported elsewhere [6]. We used GWAS meta-
analysis summary statistics (β and SE) of the three neu-
ropathologic traits for 6.5 million imputed SNPs after
omitting SNPs from studies if the minor allele frequency
was ≤ 1%, imputation quality (R2) was ≤ 0.4, or dosage
variance was ≤ 0.02.
Genome-wide pleiotropy analyses
We conducted a genome-wide pleiotropy analysis for
each pair of the three neuropathological traits using the
O’Brien method [10, 11], which is implemented in an R
library (“CUMP”) [12]. This method combines univariate
test statistics (Z-scores from β and SE values) of all SNPs
from separate GWASs for individual phenotypes to
compute a test statistic that follows a multivariate nor-
mal distribution. The covariance matrix of the distribu-
tion was approximated by the sample covariance matrix
of the test statistics of all SNPs. Under the null hypoth-
esis, an SNP is not associated with any of the pheno-
types. The alternative hypothesis is that an SNP is
associated with at least one of the phenotypes. We
defined a SNP as having a pleiotropic effect on two phe-
notypes when the P value for the O’Brien test statistic
from the joint model of association of two phenotypes
(Pjoint) with the SNP is at least one order of magnitude
more significant than the P values (Punivariate) for both
phenotypes and the univariate P values are at least nom-
inally significant (Punivariate < 0.05). As a supplementary
analysis, we also conducted a trivariate pleiotropy
genome-wide analysis for the three neuropathological
traits. The genome-wide significance (GWS) threshold
for these analyses was set at P < 5.0 × 10−8.
Gene-based association
We performed genome-wide gene-based tests for each
joint model using results from individual SNP tests.
SNPs within 30 kb of the transcription start and end
sites were included in each gene-based test. These ana-
lyses were carried out using the versatile gene-based test
(“VEGAS”) method [13], which computes an empirical P
value through Monte Carlo simulations based on linkage
disequilibrium patterns of the European ancestry popu-
lation in the 1000 Genomes Project (GRCh37 released
March 2012). The GWS level for the gene-based tests
was set at 2.7 × 10−6, which was calculated as the nom-
inal significance level 0.05 divided by the total number
of genes tested (n = 18,500).
Expression quantitative trait locus analysis
The association of SNP genotypes with gene-level expres-
sion (i.e., expression quantitative trait loci [eQTLs]) was
evaluated using version 6 of the GTEx Portal database
(http://www.gtexportal.org/; [14]) and data from the Mayo
Clinic brain expression GWAS (eGWAS) (https://www.sy
napse.org/#!Synapse:syn3157249 or http://alois.med.upen
n.edu/niagads; [15]). The GTEx Portal provides eQTL as-
sociation summary statistics (β and P values) across 43
different tissues from 175 subjects. The Mayo Clinic brain
Chung et al. Alzheimer's Research & Therapy  (2018) 10:22 Page 2 of 12
eGWAS data were generated from the cerebellum (CER;
197 AD and 177 non-AD control subjects) and temporal
cortex (TCX; 202 AD and 197 non-AD control subjects)
regions. Gene expression measures for 24,526 probes were
generated with the Illumina Whole Genome DASL array
(Illumina, San Diego, CA, USA). SNP genotype data for
the Mayo Clinic eGWAS were obtained from the Mayo
Clinic late-onset AD GWAS [16]. AD cases were diag-
nosed as definite AD according to National Institute of
Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria, whereas non-AD controls had other neuropathol-
ogies. For each brain region, association of gene expres-
sion and imputed SNP genotype (GRCh36) was evaluated
using linear regression, including covariates for AD status,
apolipoprotein E (APOE) ε4 dosage (0, 1, or 2), age at
death, sex, plate, RNA integrity number (RIN), and ad-
justed RIN (RIN − RINmean2). Analyses were also con-
ducted for AD cases and controls separately.
Differential gene expression analysis
Differential gene expression (DGE) analysis was performed
using publicly available brain whole-transcriptome RNA-
sequencing (RNA-Seq) data [17] and microarray data (Gene
Expression Omnibus accession number [GEO:GSE44772]
[18]). The RNA-Seq data include DGE summary statistics
for the CER and TCX derived from 86 patients with AD
and 80 control subjects (https://www.synapse.org). Follow-
ing a quality control step, 80 AD and 76 control brains
were analyzed. All subjects underwent RNA-Seq using the
Illumina HiSeq 2000 sequencing system (101 bp, paired-
end sequencing) at the Mayo Clinic Genomic Core Facility.
All AD and some of the control brains were from the Mayo
Clinic Brain Bank, whereas other control brains were from
the Banner Sun Health Research Institute (Sun City, AZ,
USA). Following quality control, raw read counts normal-
ized according to conditional quantile normalization
(CQN) employing the Bioconductor package were used in
the analyses. For DGE comparing AD with controls, multi-
variable linear regression analyses were conducted in R,
using CQN normalized gene expression measures and in-
cluding age at death, sex, RIN, brain tissue source, and flow
cell as biological and technical covariates. To account for
any CNS cell-population changes that occur as a conse-
quence of disease pathology, we also included cell-specific
gene levels as covariates, using the expression levels for the
five central nervous system (CNS)-specific genes as follows:
ENO2 for neurons [ENCODE:ENSG00000111674], GFAP
for astrocytes [ENCODE:ENSG00000131095], CD68 for
microglia [ENCODE:ENSG00000129226], OLIG2 for oligo-
dendrocytes [ENCODE:ENSG00000205927], and CD34 for
endothelial cells [ENCODE:ENSG00000174059].
The microarray gene expression data were generated
from autopsied brains collected from dorsolateral prefrontal
cortex (DLPFC), visual cortex (VCX), and CER regions of
129 AD patients and 101 control subjects. Samples were
profiled on a custom-made Agilent 44K array (Agilent
Technologies, Santa Clara, CA, USA) containing 40,638
human genes. Gene expression data were normalized using
Rosetta Resolver gene expression analysis software as previ-
ously described [18]. The association between expression of
each gene (outcome) and AD status (predictor) was tested
using linear regression adjusting for RIN, postmortem
interval, batch, preservation method, pH in tissues, age, sex,
and the five cell-type markers.
Results
NP, NFT, and CAA were moderately correlated (NP-NFT,
r = 0.68; NP-CAA, r = 0.56; NFT-CAA, r = 0.40; P < 2.2 ×
10−16 for each pair of traits), indicating a potential for dis-
covery of novel associations in pleiotropy analysis.
Bivariate GWAS results
There was no inflation in P values for the GWAS of the
three neuropathological traits analyzed individually
(genomic control parameter, λ = 1.00, 1.01, and 0.96 for NP,
NFT, and CAA, respectively) or as joint outcomes
(Additional file 1: Figure S1). Results of the pleiotropy
GWAS are shown in Additional file 1: Figure S2. As re-
ported previously, with the exception of APOE, only 15 of
25 previously known AD loci attained at least a nominal
association with NP, NFT, or CAA [6]. Three of the previ-
ously established AD loci—BIN1, HLA region, and
PICALM—were moderately associated (P < 10−4) in the
pleiotropy analysis for NP and NFT at a significance level of
at least one order of magnitude smaller compared with the
results from univariate analyses (Additional file 1: Table
S2). Two novel GWS associations were detected in the plei-
otropy analyses (Table 1, Fig. 1). rs34487851, an SNP lo-
cated approximately 40 kb upstream of C2orf40, was
associated with the joint model of NP and NFT (Pjoint = 2.0
× 10−8). An intronic SNP in HDAC9, rs79524815, was asso-
ciated with the joint model of NFT and CAA (Pjoint = 1.1 ×
10−8). The major allele A of rs34487851 and the minor al-
lele G of rs79524815 are associated with increased NP and
NFT and with increased NFT and the presence of CAA, re-
spectively. Both of these findings were at least one order of
magnitude more significant than for the univariate traits
(Table 1) and were supported by evidence from multiple
SNPs at those locations (Fig. 1, Additional file 1: Table S3).
Bivariate gene-based pleiotropy analysis results
Three contiguous novel genes on chromosome 2p25.3
(TRAPPC12, TRAPPC12-AS1, and ADI1) were associated
with the joint model of NFT and CAA at a gene-wide
significant level (P ≤ 2.0 × 10−6) (Table 2 and Additional
file 1: Figure S3). Of note, one SNP in this region
(rs35067331 in TRAPPC12) was associated with the NFT-
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CAA outcome at nearly the GWS level (Pjoint = 5.8 × 10
−8)
(Additional file 1: Table S4).
Trivariate GWAS and gene-based pleiotropy analysis
results
We conducted trivariate GWAS and gene-based associ-
ation analyses to identify genetic factors common to NP,
NFT, and CAA. There was no evidence for genomic
inflation (λ = 0.99) in the results from the trivariate
model (Additional file 1: Figure S4). GWS associ-
ation was observed only for APOE isoform SNP
rs429358 (P = 2.1 × 10−47), whereas associations at
C2orf40, HDAC9, and TRAPPC12 were attenuated
(Additional file 1: Table S5).
Fig. 1 Regional association plots of (a) C2orf40 from the joint model of neuritic plaque (NP) and neurofibrillary tangles (NFT) and (b) HDAC9 from
the joint model of NFT and cerebral amyloid angiopathy (CAA)
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eQTL analysis
We performed eQTL association analysis to examine
whether the expression levels of the five GWS significant
genes identified in the pleiotropy association tests dif-
fered between carriers and noncarriers of the risk alleles
from those loci. Because information about the two
GWS SNPs was not available in the GTEx Portal data-
base or in the Mayo Clinic brain eGWAS, we analyzed
proxy SNPs that are in high linkage disequilibrium (LD;
D′ ≥ 80) with the GWS SNPs. According to GTEx,
rs34487851 proxy SNP rs1232803 is a cis-acting eQTL,
and the major allele A, which is associated with higher
NP and NFT, is also significantly associated with
decreased expression of C2orf40 in several tissues, in-
cluding the esophagus (P = 3.5 × 10−5), transverse colon
(P = 4.7 × 10−4), and tibial artery (P = 1.7 × 10−3), but
not in any brain regions. In the Mayo Clinic brain
eGWAS, proxy SNPs for rs34487851 were not cis-acting
eQTLs for C2orf40. In GTEx, proxy SNPs for rs79524815
were not associated with the expression of HDAC9.
However, in the brain eGWAS, the minor alleles of proxy
SNPs for rs79524815, which are associated with higher
NFT and CAA, were significantly associated with lower
HDAC9 levels in the CER (probe ID: ILMN_1803563; best
eQTL, rs4721721; P = 0.003) but not in the TCX
(Additional file 1: Table S3). According to GTEx,
rs35067331 is a cis-acting eQTL, and its major allele C,
which is associated with higher NFT and CAA, is signifi-
cantly associated with increased expression of TRAPPC12-
AS1 in several brain regions (best P = 2.1 × 10−7 in cortex)
and ADI1 (P = 0.03) in the caudate nucleus, but not
with differential expression of TRAPPC12 in any
brain regions (Additional file 1: Table S4). In the
Mayo Clinic brain eGWAS data, rs35067331 and its
proxy SNPs were not cis-acting eQTLs for ADI1 or
TRAPPC12. Unfortunately, information about
TRAPPC12-AS1 was unavailable in the brain eGWAS.
Differential gene expression analysis
We investigated whether the expression levels of C2orf40,
HDAC9, and TRAPPC12/TRAPPC12-AS1/ADI1 differed
in AD brains compared with non-AD control brains in
the publicly available RNS-Seq and microarray datasets
(Table 3 and Fig. 2). There were no significant differences
in C2orf40 expression between subjects with AD and con-
trol subjects in the TCX or CER in the Mayo Clinic RNA-
Seq DGE profiling. However, C2orf40 was significantly
downregulated in subjects with AD compared with control
subjects in the CER (P = 1.6 × 10−3), DLPFC (P = 0.04),
and VCX (P = 2.7 × 10−3) in the microarray brain expres-
sion data. HDAC9 was significantly downregulated in sub-
jects with AD compared with control subjects in several
brain regions, including the TCX (P = 1.5 × 10−4) and CER
(P = 0.04) in the RNA-Seq profiling data and in the DLPFC
Table 2 Gene-wide significant results (P < 2.7 × 10−6) from gene-based tests of pleiotropy single-nucleotide polymorphism
association results
Univariate gene-based tests Pleiotropy gene-based tests
Chromosome Start End Gene NP NFT CAA NP + NFT NP + CAA NFT + CAA
2 3,383,446 3,483,342 TRAPPC12 0.09 4.0 × 10−5 0.5 0.01 0.07 2.0 × 10−6
2 3,485,013 3,486,180 TRAPPC12-AS1 0.002 3.9 × 10−5 5.0 × 10−3 1.6 × 10−5 2.1 × 10−5 < 1.0 × 10−6
2 3,501,690 3,523,350 ADI1 0.003 1.6 × 10−5 7.0 × 10−4 3.2 × 10−5 4.0 × 10−6 < 1.0 × 10−6
Abbreviations: NP Neuritic plaque, NFT Neurofibrillary tangles, CAA Cerebral amyloid angiopathy
Gene-based P values were computed through 1 million permutations, so the smallest P value is 1.0 × 10−6
Table 3 Results of differential gene expression analysis in brain
RNA-Seq Microarray
CER TCX CER DLPFC VCX
Gene β value (SE) P value β value (SE) P value β value (SE) P value β value (SE) P value β value (SE) P value
ECRG4a 0.06 (0.20) 0.77 0.19 (0.24) 0.43 −0.18 (0.05) 1.6 × 10−3 −0.12 (0.06) 0.04 −0.12 (0.04) 2.7 × 10−3
HDAC9 −0.24 (0.12) 0.04 −0.31 (0.08) 1.5 × 10−4 −0.01 (0.02) 0.77 −0.09 (0.03) 7.9 × 10−3 −0.06 (0.02) 5.6 × 10−4
TRAPPC12 −0.05 (0.06) 0.35 −0.13 (0.05) 0.01 −0.09 (0.03) 1.1 × 10−3 −0.03 (0.02) 0.09 −0.08 (0.02) 3.2 × 10−4
TRAPPC12-AS1 0.22 (0.12) 0.06 0.59 (0.18) 1.3 × 10−3 – – – – – –
ADI1 −0.10 (0.08) 0.19 −0.07 (0.08) 0.36 −0.10 (0.03) 4.9 × 10−4 −0.03 (0.03) 0.31 −0.01 (0.03) 0.64
Abbreviations: CER Cerebellum, TCX Temporal cortex, DLPFC Dorsolateral prefrontal cortex, CER Cerebellum, TCX Temporal cortex, DLPFC Dorsolateral prefrontal
cortex, VCX Visual cortex
Results were obtained from analyses of RNA-Seq data in the Synapse database (https://www.synapse.org; [17]) and microarray data in the Gene Expression
Omnibus database [GEO:GSE44771]. Negative β value indicates lower level of gene expression in AD cases compared with controls and vice versa. Results that
remained significant after multiple test correction (P = 0.05/22 = 2.27 × 10−3) are highlighted in bold
aAlso known as C2orf40
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Fig. 2 Box plots showing differential expression in microarray data [GEO:GSE44772] between AD cases and controls for C2orf40, HDAC9, TRAPPC12,
and ADI1 in the cerebellum (CER; left column), dorsolateral prefrontal cortex (DLPFC; middle column), and visual cortex (VCX; right column). AD
Alzheimer’s disease
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(P = 7.9 × 10−3) and VCX (P = 5.6 × 10−4) in the microarray
expression data. ADI1 expression was downregulated in
subjects with AD in the CER in the microarray data
(P = 4.9 × 10−4). The RNA-Seq DGE profiling indi-
cated that TRAPPC12-AS1 expression was signifi-
cantly increased in subjects with AD in the TCX (P =
1.3 × 10−3). In contrast, expression of TRAPPC12 was
significantly lower in subjects with AD than in con-
trol subjects in the TCX (P = 0.01) in the RNA-Seq
and in the CER (P = 1.1 × 10−3) and VCX (P = 3.2 ×
10−4) in the microarray data. Information about ex-
pression of TRAPPC12-AS1 was not available in the
microarray data. The majority of these nominally sig-
nificant findings survived correction for multiple test-
ing (P < 2.27 × 10−3).
To contextualize our findings, we evaluated DGE
among AD cases and controls for 26 previously estab-
lished AD genes (Additional file 1: Table S6) [19–21].
With notable exceptions of EPHA1 (P = 2.8 × 10−7) and
SLC24A4 (P = 7.0 × 10−5) in CER in the RNA-Seq data
and ABCA7 in DLPFC (P = 2.5 × 10−7) and VCX (P = 4.9
× 10−7) in the microarray data, none of the results for the
other 23 genes were significant after correcting for 127
tests (P < 3.94 × 10−4).
Discussion
A previous GWAS of neuropathologic traits including
NP, NFT, and CAA identified GWS associations with
APOE only [6]. Our pleiotropy analysis of all pairwise
combinations of these traits identified GWS associa-
tions with APOE and three regions not previously re-
ported with any neuropathologic traits or AD risk,
including C2orf40 for the joint model comprising NP
and NFT, as well as HDAC9 and TRAPPC12/
TRAPPC12-AS1/ADI1 for the joint model comprising
NFT and CAA. Our DGE study found that HDAC9 is
significantly downregulated in several brain regions in
subjects with AD compared with control subjects.
Moreover, we observed that the G allele of HDAC9
SNP rs79524815 is associated with a higher level of
the joint outcome of NFT and CAA, and proxy SNPs
for rs79524815 (which are suggestively associated with
the joint outcome of NFT and CAA) are associated
with decreased HDAC9 expression in subjects with
AD (Additional file 1: Table S3). The pleiotropy ana-
lysis also revealed that 4 (BIN1, HLA, PICALM, and
APOE) of the 25 previously reported GWS AD risk
loci [7, 19–21] were at least one order of magnitude
more significantly associated with the joint model of NP +
NFT than each of these traits analyzed separately, suggest-
ing that these genes are involved in pathways leading to
both plaques and tangles [22–25].
It is notable that pleiotropy analyses for the model
including NP, NFT, and CAA did not yield any GWS
findings. Moreover, the GWS associations identified in
the bivariate models were attenuated in the trivariate
model. These results suggest that the mechanisms or
pathways underlying the bivariate associations prob-
ably do not encompass all three traits, and this con-
clusion may generalize genome-wide.
C2orf40, also known as esophageal cancer-related gene
4 (ECRG4), is a tumor suppressor gene [26] that encodes
a peptide hormone that is involved in NFT formation in
transgenic mice [27], senescence of precursor cells in
the CNS during aging [28], and activation of microglia
and peripheral mononuclear leukocytes [29]. We ob-
served that rs34487851 allele A is associated with higher
NP and NFT and lower expression of ERCG4, albeit not
in the brain. We also found that ERCG4 expression was
significantly lower in AD cases than in controls in sev-
eral brain regions. Abnormal downregulation of C2orf40
was previously reported in brain injury [30] as well as in
several cancer cell types [31, 32].
HDAC9 encodes a member of class IIa histone genes
that deacetylate histones, thereby remodeling chromatin
structure and controlling gene expression [33, 34] that
has previously been linked to epigenetic mechanisms
[35] and memory loss [36] in AD and also has been pro-
posed as a possible therapeutic target [37–39]. GWS as-
sociation of ischemic stroke with an HDAC9 variant was
identified by GWAS [40]. Structural variants including
deletions and copy number variants in HDAC9 have
been identified in patients with schizophrenia and
patients with autism [41, 42]. MEF2C, one of the well-
established AD risk loci [21], stimulates HDAC9 expres-
sion, but HDAC9 suppresses MEF2C transcription,
resulting in a negative feedback loop [43]. In a previously
reported coexpression network study in AD and con-
trol brains, HDAC9 and MEF2C were clustered to-
gether in the top fourth module ranked by relevance
to AD pathology, and expression of HDAC9 and
MEF2C was inversely correlated with Braak stage
(HDAC9, r = −0.71; MEF2C, r = −0.65) and frontal
atrophy (HDAC9, r = −0.57, MEF2C, r = −0.51) [18].
These findings are consistent with our observation
that HDAC9 expression is reduced in subjects with
AD and in the subjects with HDAC9 SNP alleles as-
sociated with higher NFT and CAA. Decreased
HDAC9 expression has also been linked to increased
neuronal apoptosis [44, 45]. Collectively, findings
from our and other studies indicate that MEF2C and
HDAC9 may participate in a pathway leading to NFT
formation and brain atrophy.
Gene-based analyses identified significant associations
with three adjacent loci—TRAPPC12, TRAPPC12-AS1,
and ADI1—in a gene-rich region near the end of the
short arm of chromosome 2p. ADI1, encoding acireduc-
tone dioxygenase 1, is involved in methionine salvage
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and prostate cancer [46] and has no known relationship
to AD. TRAPPC12 is a subunit of a trafficking protein
particle complex that has a role in vesicle trafficking in
endoplasmic reticulum (ER) to Golgi [47]. TRAPPC12-
AS1 is an antisense (noncoding) RNA that contains a
1168 transcript from TRAPPC12. We previously estab-
lished that regulation of vesicular trafficking in the ER to
Golgi by several VPS10 receptor domain receptor genes,
including SORL1, and by other genes encoding members
of the retromer complex is an important pathway lead-
ing to AD [48–50]. Of the genes in this region, only
TRAPPC12-AS1 showed a pattern of expression in sub-
jects with AD and control subjects that is consistent
with the effect direction of the TRAPPC12 rs35067331
allele’s influence on NFT and CAA. It should be noted
that TRAPPC12 expression was significantly lower in
AD cases than in control subjects in the TCX (P = 0.01)
in the RNA-Seq data and the CER (P = 1.1 × 10−3) and
VCX (P = 3.2 × 10−4) in the microarray data, which
could be due to negative feedback by the antisense
TRAPPC12-AS1 transcript [51].
Our study has several potential caveats. The GWS
associations identified in the pleiotropy analysis have
moderate supportive evidence for association from
other SNPs under the association peaks, probably
because of low LD with the top SNPs. The two
GWS SNPs near C2orf40 and HDAC9 were not asso-
ciated with AD risk in one of the largest GWASs for
AD (rs34487851, P = 0.07; rs79524815, P = 0.73)
[19, 21]. However, approximately 87% of the autopsy
samples used in this pleiotropy analysis (as well as
in the Beecham et al. study [6]) were from patients
with AD. This may indicate that our findings are
more relevant with neuropathological progression
after onset of AD clinical symptoms. Alternatively,
because our study was focused on endophenotypes
that might be more proximal than disease diagnosis
to effects of the genetic variants [52, 53], our ana-
lyses might have more power to detect those novel
associations. Finally, to our knowledge, additional
large late-onset AD cohorts with neuropathological
and genotype data are not currently available for
replication of our association findings. Therefore,
validation of the role of these loci in AD will likely
require experimental evidence.
Conclusions
Our findings suggest that genome-wide pleiotropy
analysis is a useful approach to identifying novel gen-
etic associations with complex diseases and their
endophenotypes. Functional studies are needed to de-
termine whether C2orf40 or HDAC9 is a plausible
therapeutic target.
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